Episode 57: Endocrinology – The Audio PANCE/PANRE Board Review Podcast – Content Blueprint Review Endocrinology

The Audio PANCE/PANRE PA Board Review Podcast Welcome to episode 57 of the FREE Audio PANCE and PANRE Physician Assistant Board Review Podcast. Join me as I cover ten PANCE and PANRE Board review questions from the SMARTYPANCE course content following the NCCPA™ content blueprint (download the FREE cheat sheet). This week we will be covering ten endocrinology board review questions based on the NCCPA PANCE and PANRE Content Blueprint.  Below you will find an interactive exam to complement the podcast. I hope you enjoy this free audio component to the examination portion of this site. The full board review includes over 2,000 interactive board review questions and is available to all members of the PANCE and PANRE Academy and SMARTYPANCE which are now bundled together into one very low price. You can download and listen to past FREE episodes here, on iTunes, on Google Play Music or Stitcher Radio. You can listen to the latest episode, take an interactive quiz and download your results below. Listen Carefully Then Take The Practice Exam If you can't see the audio player click here to listen to the full episode. Episode 57 - Endocrinology PANCE/PANRE Podcast Quiz The following 10 questions are linked to NCCPA Content Blueprint lessons from the SMARTYPANCE and PANRE Board review website. If you are a member you will be able to log in and view this interactive video content. 1. A 53-year-old Hispanic woman comes to your clinic for her annual physical exam. She is obese, does not exercise, and regularly eats fried foods. A random blood glucose is 249 mg/dL. Her hemoglobin A1C is 9.5. Which of the following treatments would be weight neutral or cause weight loss in this patient? A. Glargine B. Glyburide C. Actos D. Metformin E. Glipizide Diabetes Mellitus Type 2 is covered as part of the NCCPA Endocrinology Content Blueprint which accounts for 6% of your exam. Click here to see the answer Answer: D. Metformin The patient in this vignette most likely has type II diabetes. Of the given treatments, only metformin is weight neutral in the majority of cases (i.e. it does not cause significant weight gain/loss). Metformin is a first-line treatment for type II DM in most patients. Although the exact mechanism is unknown, it appears to decrease gluconeogenesis and increase insulin sensitivity. There is no risk of hypoglycemia or weight gain (though some patients even lose weight). The most high yield side effect involves lactic acidosis, particularly in patients with renal insufficiency.  A. Glargine, a long-acting insulin, can cause weight gain. B. Glyburide, a second-generation sulfonylurea, can cause weight gain. C. Actos, a thiazolidinedione, can cause weight gain. E. Glipizide, a second-generation sulfonylurea, can cause weight gain. 2. A solitary thyroid nodule is noted on physical examination. The TSH level is normal. The next step in the evaluation is: A. measurement of T4 and free T3 levels. B. a radionuclide thyroid scan. C. a fine needle biopsy. D. a surgical excision. Solitary thyroid nodule is covered as part of thyroid neoplastic disease in the NCCPA Endocrinology Content Blueprint which accounts for 6% of your exam. Click here to see the answer Answer: C. a fine needle biopsy Fine needle aspiration (FNA) is the first step in the evaluation of a solitary nodule with a normal TSH level. FNA has a high level of accuracy in diagnosing benign versus malignant nodules in this setting. A. Measurement of T4 and T3 levels would not be of benefit in the evaluation of a solitary thyroid nodule with a normal TSH level. B. A thyroid scan would be the next step if there were a low TSH level. D. Surgical excision would be the final step after determination of malignancy or suspicion of malignancy by FNA. 3. An 18-year-old male with a past medical history of type I diabetes presents to the emergency room with polyuria, polydipsia,